Sanofi Receives Two Bids Valuing Its Consumer Health Unit at Around $17 Billion: Bloomberg
Sanofi (NASDAQ: SNY) has received two separate bids from private equity firms for its consumer health unit, which could be […]
Sanofi (NASDAQ: SNY) has received two separate bids from private equity firms for its consumer health unit, which could be […]
NEW YORK – Sanofi’s (NASDAQ: SNY) chief executive, Paul Hudson, said in an interview on Monday that the company is
Sanofi (NASDAQ: SNY) CEO Believes New Drugs Will Drive Company Growth Read More »
On Friday, the U.S. Food and Drug Administration said it has approved the use of a drug combination along with
FRANKFURT – On Friday, Sanofi (NASDAQ: SNY) said that its multiple sclerosis drug candidate was shown to delay the worsening
Sanofi (NASDAQ: SNY) Reports Key Milestone in Multiple Sclerosis Drug Development Read More »
Sanofi’s (NASDAQ: SNY) most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat
Sanofi’s (NASDAQ: SNY) Mixed Fortunes in MS Drug Trials Has Market Focus on Win Read More »
On Thursday, Sanofi (NASDAQ: SNY) raised its full-year profit outlook after strong demand for blockbuster asthma drug Dupixent and better-than-expected
HYDERABAD – French drugmaker Sanofi (NASDAQ: SNY) plans to invest 400 million euros ($437.24 million) in its global capacity center
Sanofi (NASDAQ: SNY) Eyes Major Expansion in India with $437 Million Investment Read More »
Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi’s (NASDAQ: SNY)
Sanofi (NASDAQ: SNY) Consumer Health Unit Attracts Interest from Bpifrance Read More »
On Wednesday, Sanofi (NASDAQ: SNY) and partner Regeneron (NASDAQ: REGN) won European Union approval for wider use of their Dupixent
Sanofi (NASDAQ: SNY) Win EU Approval for Dupixent in Chronic Lung Disease Read More »